Autolus expects full-year 2026 AUCATZYL net product revenue at or above $150M, as BOBCAT data shifts to October 2027

What happened: Autolus Therapeutics reported Q3 2026 results driven by AUCATZYL commercialization, and management guided full-year 2026 AUCATZYL net product revenue to at or above $150M while shifting BOBCAT data to October 2027. Key numbers: Q3 2026 AUCATZYL net revenues of $41.2 million; 90 centers onboarded; FY 2026 AUCATZYL net product revenue guidance at or above $150M; BOBCAT data now expected Why it matters: Center onboarding is described as progressing ahead of plan, and the revenue guidance sets a full-year target for the launch. The BOBCAT data timeline moves to October 2027.

Autolus Therapeutics reported Q3 2026 results driven by AUCATZYL commercialization, and management guided full-year 2026 AUCATZYL net product revenue to at or above $150M while shifting BOBCAT data to October 2027.

Center onboarding is described as progressing ahead of plan, and the revenue guidance sets a full-year target for the launch. The BOBCAT data timeline moves to October 2027.